Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)

NCT: NCT07219745 · NOT_YET_RECRUITING

NCT IDNCT07219745
StatusNOT_YET_RECRUITING
Start Date2026-10
Completion2027-11
SponsorCase Comprehensive Cancer Center (OTHER)
First posted
Last updated

Brief Summary

Transanal irrigation (TAI) has shown to improve fecal incontinence and increase quality of life in patients with low anterior resection syndrome (LARS). This trial is a small study being conducted to determine whether a larger trial is feasible. Investigators are also doing this research to see if TAI impacts quality of life and improves bowel function within the early post-operative period (1-12 months). This treatment is designed for participants to have more control over their bowel movements and reduce the dependency on immediate access to the toilet.

Frequently Asked Questions

What is Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)?

Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS) is a clinical trial registered under NCT07219745. Current status: NOT_YET_RECRUITING.

What is the status of NCT07219745?

The current status of NCT07219745 (Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)) is: NOT_YET_RECRUITING.

When did Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS) start?

Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS) started on 2026-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.